A recent study by Okamoto et al. [41] using 177Lu-PSMA-I&T demonstrated gradually decreasing tumor dose estimates from one cycle to the other and correlation between pre-therapeutic SUV values and absorbed tumor dose estimates. This evidence concerns the gene FOLH1 and neoplasm.